Theratechnologies (THTX)
(Delayed Data from NSDQ)
$1.55 USD
-0.02 (-0.96%)
Updated Jul 23, 2024 03:59 PM ET
After-Market: $1.54 -0.01 (-0.32%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Theratechnologies Inc falls in the month of November.
All items in Millions except Per Share data.
11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 40 | 33 | 40 | 21 | 41 |
Receivables | 14 | 12 | 11 | 13 | 10 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 20 | 29 | 25 | 21 |
Other Current Assets | 3 | 8 | 11 | 6 | 5 |
Total Current Assets | 63 | 73 | 92 | 65 | 76 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 1 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 2 | 1 | 0 | 0 |
Intangibles | 13 | 15 | 21 | 25 | 27 |
Deposits & Other Assets | 0 | 0 | 2 | 7 | 12 |
Total Assets | 78 | 93 | 119 | 100 | 118 |
Liabilities & Shareholders Equity | 11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 28 | 41 | 40 | 35 | 31 |
Current Portion Long-Term Debt | 7 | 65 | 0 | 5 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11 | 8 | 4 | 2 | 3 |
Total Current Liabilities | 47 | 114 | 45 | 42 | 37 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 54 | 52 | 51 |
Long-Term Debt | 51 | 0 | 0 | 0 | 5 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 99 | 116 | 101 | 97 | 93 |
Shareholders Equity | 11/30/2023 | 11/30/2022 | 11/30/2021 | 11/30/2020 | 11/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 364 | 339 | 336 | 287 | 287 |
Capital Surplus | 23 | 19 | 13 | 12 | 11 |
Retained Earnings | -409 | -383 | -335 | -300 | -277 |
Other Equity | 1 | 3 | 4 | 4 | 4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -21 | -23 | 18 | 3 | 25 |
Total Liabilities & Shareholder's Equity | 78 | 93 | 119 | 100 | 118 |
Total Common Equity | -21 | -23 | 18 | 3 | 25 |
Shares Outstanding | 45.90 | 24.20 | 23.70 | 19.20 | 19.20 |
Book Value Per Share | -0.45 | -0.93 | 0.75 | 0.17 | 1.29 |
Fiscal Year End for Theratechnologies Inc falls in the month of November.
All items in Millions except Per Share data.
5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 36 | 38 | 40 | 23 | 25 |
Receivables | 14 | 11 | 14 | 9 | 14 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | 6 | 6 | 6 | 7 | 9 |
Other Current Assets | 2 | 3 | 3 | 2 | 3 |
Total Current Assets | 57 | 58 | 63 | 41 | 51 |
Net Property & Equipment | 0 | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 1 | 2 |
Intangibles | 12 | 12 | 13 | 13 | 14 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | 70 | 72 | 78 | 57 | 69 |
Liabilities & Shareholders Equity | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | 26 | 30 | 28 | 30 | 34 |
Current Portion Long-Term Debt | 17 | 12 | 7 | 57 | 27 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | 8 | 8 | 11 | 10 | 10 |
Total Current Liabilities | 52 | 50 | 47 | 98 | 71 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | 41 | 46 | 51 | 0 | 38 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | 93 | 97 | 99 | 98 | 110 |
Shareholders Equity | 5/31/2024 | 2/29/2024 | 11/30/2023 | 8/31/2023 | 5/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | 364 | 364 | 364 | 339 | 339 |
Capital Surplus | 24 | 24 | 23 | 23 | 20 |
Retained Earnings | -412 | -413 | -409 | -404 | -403 |
Other Equity | 1 | 1 | 1 | 1 | 3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -23 | -25 | -21 | -42 | -42 |
Total Liabilities & Shareholder's Equity | 70 | 72 | 78 | 57 | 69 |
Total Common Equity | 99,976 | -25 | -21 | -42 | -42 |
Shares Outstanding | 45.90 | 45.90 | 45.90 | 24.20 | 24.20 |
Book Value Per Share | 2,178.12 | -0.54 | -0.45 | -1.72 | -1.72 |